CTLA4-Ig

Sarah E. Yost, Bruce Kaplan

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Modern-day immunosuppression relies heavily on calcineurin inhibitors (CNIs) such as cyclosporine and tacrolimus. While dramatically reducing the rates of acute cellular rejection over the last couple of decades, these agents have numerous undesirable metabolic and cosmetic side effects. In the past, immunosuppression was based on small molecular therapy, including CNIs, prodrugs of mycophenolate mofetil, and these drugs had many undesirable side effects. Biological agents are now more frequently tested for immunosuppression, including monoclonal antibodies, agents that block stimulatory pathways, and specific receptors. Recent studies with the agent belatacept have shown promise in terms of eliminating CNIs and also eliminating the burden of toxicities that accompany their use.

Original languageEnglish (US)
Title of host publicationImmunotherapy in Transplantation: Principles and Practice
PublisherWiley-Blackwell
Pages399-406
Number of pages8
ISBN (Print)9781405182713
DOIs
StatePublished - Apr 19 2012
Externally publishedYes

Fingerprint

Immunosuppression
Mycophenolic Acid
Prodrugs
Biological Factors
Tacrolimus
Cosmetics
Cyclosporine
Monoclonal Antibodies
Pharmaceutical Preparations
Abatacept
Calcineurin Inhibitors
Therapeutics

Keywords

  • Abatacept
  • Belatacept
  • Immunosuppression
  • ITLA4-Ig

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Yost, S. E., & Kaplan, B. (2012). CTLA4-Ig. In Immunotherapy in Transplantation: Principles and Practice (pp. 399-406). Wiley-Blackwell. https://doi.org/10.1002/9781444355628.ch27

CTLA4-Ig. / Yost, Sarah E.; Kaplan, Bruce.

Immunotherapy in Transplantation: Principles and Practice. Wiley-Blackwell, 2012. p. 399-406.

Research output: Chapter in Book/Report/Conference proceedingChapter

Yost, SE & Kaplan, B 2012, CTLA4-Ig. in Immunotherapy in Transplantation: Principles and Practice. Wiley-Blackwell, pp. 399-406. https://doi.org/10.1002/9781444355628.ch27
Yost SE, Kaplan B. CTLA4-Ig. In Immunotherapy in Transplantation: Principles and Practice. Wiley-Blackwell. 2012. p. 399-406 https://doi.org/10.1002/9781444355628.ch27
Yost, Sarah E. ; Kaplan, Bruce. / CTLA4-Ig. Immunotherapy in Transplantation: Principles and Practice. Wiley-Blackwell, 2012. pp. 399-406
@inbook{64f11ca5818b4cacbbb38cff97af22b9,
title = "CTLA4-Ig",
abstract = "Modern-day immunosuppression relies heavily on calcineurin inhibitors (CNIs) such as cyclosporine and tacrolimus. While dramatically reducing the rates of acute cellular rejection over the last couple of decades, these agents have numerous undesirable metabolic and cosmetic side effects. In the past, immunosuppression was based on small molecular therapy, including CNIs, prodrugs of mycophenolate mofetil, and these drugs had many undesirable side effects. Biological agents are now more frequently tested for immunosuppression, including monoclonal antibodies, agents that block stimulatory pathways, and specific receptors. Recent studies with the agent belatacept have shown promise in terms of eliminating CNIs and also eliminating the burden of toxicities that accompany their use.",
keywords = "Abatacept, Belatacept, Immunosuppression, ITLA4-Ig",
author = "Yost, {Sarah E.} and Bruce Kaplan",
year = "2012",
month = "4",
day = "19",
doi = "10.1002/9781444355628.ch27",
language = "English (US)",
isbn = "9781405182713",
pages = "399--406",
booktitle = "Immunotherapy in Transplantation: Principles and Practice",
publisher = "Wiley-Blackwell",

}

TY - CHAP

T1 - CTLA4-Ig

AU - Yost, Sarah E.

AU - Kaplan, Bruce

PY - 2012/4/19

Y1 - 2012/4/19

N2 - Modern-day immunosuppression relies heavily on calcineurin inhibitors (CNIs) such as cyclosporine and tacrolimus. While dramatically reducing the rates of acute cellular rejection over the last couple of decades, these agents have numerous undesirable metabolic and cosmetic side effects. In the past, immunosuppression was based on small molecular therapy, including CNIs, prodrugs of mycophenolate mofetil, and these drugs had many undesirable side effects. Biological agents are now more frequently tested for immunosuppression, including monoclonal antibodies, agents that block stimulatory pathways, and specific receptors. Recent studies with the agent belatacept have shown promise in terms of eliminating CNIs and also eliminating the burden of toxicities that accompany their use.

AB - Modern-day immunosuppression relies heavily on calcineurin inhibitors (CNIs) such as cyclosporine and tacrolimus. While dramatically reducing the rates of acute cellular rejection over the last couple of decades, these agents have numerous undesirable metabolic and cosmetic side effects. In the past, immunosuppression was based on small molecular therapy, including CNIs, prodrugs of mycophenolate mofetil, and these drugs had many undesirable side effects. Biological agents are now more frequently tested for immunosuppression, including monoclonal antibodies, agents that block stimulatory pathways, and specific receptors. Recent studies with the agent belatacept have shown promise in terms of eliminating CNIs and also eliminating the burden of toxicities that accompany their use.

KW - Abatacept

KW - Belatacept

KW - Immunosuppression

KW - ITLA4-Ig

UR - http://www.scopus.com/inward/record.url?scp=84885812243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885812243&partnerID=8YFLogxK

U2 - 10.1002/9781444355628.ch27

DO - 10.1002/9781444355628.ch27

M3 - Chapter

SN - 9781405182713

SP - 399

EP - 406

BT - Immunotherapy in Transplantation: Principles and Practice

PB - Wiley-Blackwell

ER -